Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy
Hubner, Richard A
Valle, Juan W
McNamara, Mairead G
AffiliationDivision of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester
MetadataShow full item record
AbstractBiliary tract cancers, including intra- and extra-hepatic cholangiocarcinoma as well as gallbladder cancer, are associated with poor prognosis and the majority of patients present with advanced-stage, non-resectable disease at diagnosis. Biliary tract cancer may develop through an accumulation of genetic and epigenetic alterations and can be influenced by microbial exposure. Furthermore, the liver and biliary tract are exposed to the gastrointestinal microbiome through the gut-liver axis. The availability of next-generation sequencing technology has led to an increase in studies investigating the relationship between microbiota and human disease. In particular, the interplay between the microbiome, the tumour micro-environment and response to systemic therapy is a prospering area of interest. Given the poor outcomes for patients with biliary tract cancer, this emerging field of research, through which new biomarkers may be identified, offers potential as a tool for early diagnosis, prognostication or even as a future therapeutic target. This review summarises the available evidence on the microbiome environment in patients with biliary tract cancer, including a discussion around confounding factors, implications for therapy and proposed future directions.
CitationWheatley RC, Kilgour E, Jacobs T, Lamarca A, Hubner RA, Valle JW, et al. Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy. British Journal of Cancer. Springer Science and Business Media LLC; 2021.
JournalBritish Journal of Cancer
- Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.
- Authors: Mao J, Wang D, Long J, Yang X, Lin J, Song Y, Xie F, Xun Z, Wang Y, Wang Y, Li Y, Sun H, Xue J, Song Y, Zuo B, Zhang J, Bian J, Zhang T, Yang X, Zhang L, Sang X, Zhao H
- Issue date: 2021 Dec
- 16S rDNA microbiome composition pattern analysis as a diagnostic biomarker for biliary tract cancer.
- Authors: Lee H, Lee HK, Min SK, Lee WH
- Issue date: 2020 Jan 24
- Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes.
- Authors: Chen X, Wang D, Liu J, Qiu J, Zhou J, Ying J, Shi Y, Wang Z, Lou H, Cui J, Zhang J, Liu Y, Zhao F, Pan L, Zhao J, Zhu D, Chen S, Li X, Li X, Zhu L, Shao Y, Shu Y
- Issue date: 2021 Nov
- Current standards and future perspectives in adjuvant treatment for biliary tract cancers.
- Authors: Lamarca A, Edeline J, McNamara MG, Hubner RA, Nagino M, Bridgewater J, Primrose J, Valle JW
- Issue date: 2020 Mar
- Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
- Authors: Chae H, Kim D, Yoo C, Kim KP, Jeong JH, Chang HM, Lee SS, Park DH, Song TJ, Hwang S, Kim KH, Song GW, Ahn CS, Lee JH, Hwang DW, Kim SC, Jang SJ, Hong SM, Kim TW, Ryoo BY
- Issue date: 2019 Oct